|
Post by joeypotsandpans on Jan 5, 2016 17:43:59 GMT -5
directly by Mannkind via internet? Before you think that is a serious statement it isn't but is said tongue in cheek with purpose....no insurance coverage WAS a huge obstacle, now there may be other opportunities as have been mentioned previously. When one door closes another opens and can be a better one. Fwiw, response from SNY rep, "we will continue to promote the product until 4/1. Then they (SNY) will transition the rights back to Mannkind. The product will remain on the market. I don't know who will promote it after that. I've communicated to my local team asking them to maintain a positive attitude with our customers about the benefits of Afrezza, regardless of the decision. I believe in the product and still want it to succeed." This wouldn't be the first time the French may end up with egg on their face along with Olivier Brandicourt for not ever giving the best prandial insulin its due. Did I read somewhere that Chris Viehbacher is working with venture funds somewhere here in the states...what an opportunity for him to pay back SNY with some embarrassment. Since there were some sports analogies previous I would throw this one out there...it could be like when the Red Sox traded the Babe to N.Y. ...https://en.wikipedia.org/wiki/Curse_of_the_Bambino After which it would be a premier case study used in business schools on how not to market a hugely viable/needed product, example SNY
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 17:47:44 GMT -5
My concern is that the small script count we have now will start to trend down. I am not a Dr so I will wait for one to chime in but would you start tapering off your patience to prepare them to go back to injectable?
|
|
|
Post by liane on Jan 5, 2016 17:49:22 GMT -5
No way!
|
|
|
Post by liane on Jan 5, 2016 17:52:47 GMT -5
joeypotsandpans, I still think in a few years Afrezza will be a paradigm shift in the treatment of diabetes and Sanofi will be known for the one that got away. Amazing how short-sighted they can be.
|
|
|
Post by peppy on Jan 5, 2016 17:56:56 GMT -5
My concern is that the small script count we have now will start to trend down. I am not a Dr so I will wait for one to chime in but would you start tapering off your patience to prepare them to go back to injectable? Going back to injectable sounds awful. Matt down under just recently has been able to eat out, because he can control his blood sugar.
(Darn) it isn't injectable, inhalable, it's quality of life. screencast.com/t/M9pjFQMUikrs
|
|
|
Post by mnholdem on Jan 5, 2016 18:16:31 GMT -5
You'd have to be from another planet not to know that Sanofi has not been reaching out to physicians. Current users will be sticking with Afrezza and with some REAL commercializing efforts, scripts will increase. IMHO.
|
|
|
Post by joeypotsandpans on Jan 5, 2016 18:31:22 GMT -5
joeypotsandpans , I still think in a few years Afrezza will be a paradigm shift in the treatment of diabetes and Sanofi will be known for the one that got away. Amazing how short-sighted they can be. Liane, nothing amazes me any more...(except having Oregon vs TCU and being up 31-0 at halftime...but that's a whole different conversation... private joke lol)....first abortion (for lack of a better term) of how to market/educate about inhalable insulin was Pfizer (even though they had a much inferior product they screwed it up), second Sanofi, the third time should be the charm with the "one that gets it" so to speak.
|
|
|
Post by bradleysbest on Jan 5, 2016 20:35:33 GMT -5
Yes but we need "one" to step up to the plate & sign on the dotted line.
|
|